UBS Group’s Mereo BioPharma MREO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.01M | Sell |
373,505
-558,516
| -60% | -$1.51M | ﹤0.01% | 4351 |
|
|
2025
Q1 | $2.1M | Sell |
932,021
-1,716,119
| -65% | -$3.86M | ﹤0.01% | 3665 |
|
|
2024
Q4 | $9.27M | Buy |
+2,648,140
| New | +$9.27M | ﹤0.01% | 2412 |
|
|
2024
Q1 | – | Sell |
-2,813
| Closed | -$6.5K | – | 8453 |
|
|
2023
Q4 | $6.5K | Buy |
+2,813
| New | +$6.5K | ﹤0.01% | 6489 |
|
|
2023
Q3 | – | Sell |
-2,491
| Closed | -$3.29K | – | 8548 |
|
|
2023
Q2 | $3.29K | Sell |
2,491
-93,666
| -97% | -$124K | ﹤0.01% | 6565 |
|
|
2023
Q1 | $68K | Sell |
96,157
-32,384
| -25% | -$22.9K | ﹤0.01% | 5136 |
|
|
2022
Q4 | $96.4K | Sell |
128,541
-38,964
| -23% | -$29.2K | ﹤0.01% | 5019 |
|
|
2022
Q3 | $144K | Buy |
167,505
+127,505
| +319% | +$110K | ﹤0.01% | 4357 |
|
|
2022
Q2 | $45K | Buy |
+40,000
| New | +$45K | ﹤0.01% | 4988 |
|
|
2022
Q1 | – | Sell |
-23,306
| Closed | -$37K | – | 9437 |
|
|
2021
Q4 | $37K | Buy |
23,306
+13,357
| +134% | +$21.2K | ﹤0.01% | 6088 |
|
|
2021
Q3 | $24K | Buy |
9,949
+9,019
| +970% | +$21.8K | ﹤0.01% | 5842 |
|
|
2021
Q2 | $3K | Sell |
930
-4,189
| -82% | -$13.5K | ﹤0.01% | 7712 |
|
|
2021
Q1 | $17K | Buy |
5,119
+480
| +10% | +$1.59K | ﹤0.01% | 6497 |
|
|
2020
Q4 | $17K | Buy |
4,639
+4,456
| +2,435% | +$16.3K | ﹤0.01% | 6043 |
|
|
2020
Q3 | $0 | Sell |
183
-782
| -81% | – | ﹤0.01% | 7276 |
|
|
2020
Q2 | $2K | Sell |
965
-855
| -47% | -$1.77K | ﹤0.01% | 6784 |
|
|
2020
Q1 | $2K | Sell |
1,820
-5,149
| -74% | -$5.66K | ﹤0.01% | 6693 |
|
|
2019
Q4 | $23K | Buy |
6,969
+5,845
| +520% | +$19.3K | ﹤0.01% | 5730 |
|
|
2019
Q3 | $3K | Buy |
1,124
+448
| +66% | +$1.2K | ﹤0.01% | 6673 |
|
|
2019
Q2 | $1K | Buy |
+676
| New | +$1K | ﹤0.01% | 6844 |
|